CA2019863C - Suspension aqueuse pharmaceutique pour des ingredients actifs pharmaceutiques peu hydrosolubles - Google Patents

Suspension aqueuse pharmaceutique pour des ingredients actifs pharmaceutiques peu hydrosolubles

Info

Publication number
CA2019863C
CA2019863C CA002019863A CA2019863A CA2019863C CA 2019863 C CA2019863 C CA 2019863C CA 002019863 A CA002019863 A CA 002019863A CA 2019863 A CA2019863 A CA 2019863A CA 2019863 C CA2019863 C CA 2019863C
Authority
CA
Canada
Prior art keywords
suspension
volume
weight
mixture
xanthan gum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002019863A
Other languages
English (en)
Other versions
CA2019863A1 (fr
Inventor
Walter G. Gowan, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Consumer Inc
Original Assignee
McNeil PPC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McNeil PPC Inc filed Critical McNeil PPC Inc
Publication of CA2019863A1 publication Critical patent/CA2019863A1/fr
Application granted granted Critical
Publication of CA2019863C publication Critical patent/CA2019863C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002019863A 1989-06-28 1990-06-26 Suspension aqueuse pharmaceutique pour des ingredients actifs pharmaceutiques peu hydrosolubles Expired - Lifetime CA2019863C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37273489A 1989-06-28 1989-06-28
US372,734 1989-06-28

Publications (2)

Publication Number Publication Date
CA2019863A1 CA2019863A1 (fr) 1990-12-28
CA2019863C true CA2019863C (fr) 1996-06-04

Family

ID=23469412

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002019863A Expired - Lifetime CA2019863C (fr) 1989-06-28 1990-06-26 Suspension aqueuse pharmaceutique pour des ingredients actifs pharmaceutiques peu hydrosolubles

Country Status (17)

Country Link
US (2) US5374659A (fr)
EP (1) EP0405930B1 (fr)
JP (1) JP2874967B2 (fr)
KR (1) KR0161969B1 (fr)
AT (1) ATE110259T1 (fr)
AU (1) AU635283B2 (fr)
CA (1) CA2019863C (fr)
DE (1) DE69011766T2 (fr)
ES (1) ES2064634T3 (fr)
GR (1) GR1002094B (fr)
GT (1) GT199000066A (fr)
HK (1) HK127494A (fr)
IE (1) IE64400B1 (fr)
IL (1) IL94887A (fr)
NZ (1) NZ234143A (fr)
PT (1) PT94504B (fr)
ZA (1) ZA905058B (fr)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0662320T3 (da) * 1991-08-30 2001-09-24 Showa Pharm Chem Ind Tør gelsammensætning
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
EP0620001A1 (fr) * 1993-04-16 1994-10-19 McNEIL-PPC, INC. Suspension pharmaceutique aqueuse et procédé pour sa préparation
FR2713931B1 (fr) * 1993-12-20 1996-04-05 Laurence Paris Nouvelles compositions pharmaceutiques liquides à base d'ibuprofène et leur procédé de préparation.
NZ272574A (en) * 1995-07-14 1999-02-25 Lilly Eli & Co Nz Ltd Aqueous base suspension concentrate containing at least one ionophore antibiotic and wetting agent and/or a surfactant and xanthan gum optionally with a suspension agent, an antifreeze agent and an antifoaming agent; drench for veterinary treatment
WO1997003650A1 (fr) * 1995-07-14 1997-02-06 Eli Lilly & Company (Nz) Limited Formulations d'antibiotiques ionophores
NZ280384A (en) 1995-11-02 1997-01-29 Lilly Eli & Co Nz Ltd Animal feed supplement comprising a wettable powder composition of an ionophore antibiotic
AUPN862596A0 (en) * 1996-03-12 1996-04-04 F.H. Faulding & Co. Limited Pharmaceutical compositions
CN1220598A (zh) * 1996-05-02 1999-06-23 大正制药株式会社 水难溶性酸性药物的悬浮液
US5712310A (en) * 1996-06-14 1998-01-27 Alpharma Uspd, Inc. Suspension of substantially water-insoluble drugs and methods of their manufacture
US20110189348A1 (en) * 1998-10-28 2011-08-04 San-Ei Gen F.F.I., Inc. Compositions containing sucralose and application thereof
US7229658B1 (en) * 1998-10-28 2007-06-12 San-Ei Gen F.F.I., Inc Compositions containing sucralose and application thereof
USH2044H1 (en) 1998-11-02 2002-09-03 Mcneil-Ppc, Inc. Container with retaining member
BR0009557A (pt) 1999-04-06 2002-05-28 Ethypharm Lab Prod Ethiques Suspensão farmacêutica para beber de ibuprofeno
US6211246B1 (en) * 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
US6726922B1 (en) 1999-06-28 2004-04-27 Minu, L.L.C. Process and composition for temporarily suppressing pain
WO2001091585A2 (fr) 2000-05-31 2001-12-06 Pepsico, Inc. Composition de coloration alimentaire orange a faible intensite de coloration
WO2002010756A2 (fr) * 2000-08-02 2002-02-07 Malope Company Limited Diagnostic et traitement de la dyspepsie non ulcereuse fondes sur l'anomalie de l'axe hypothalamo-hypophyso-surrenalien
JP4204864B2 (ja) * 2000-12-25 2009-01-07 ライオン株式会社 懸濁液の安定化方法及び安定化された懸濁液
DE60120630T2 (de) * 2001-02-14 2007-05-24 Forte Iq B.V. Pharmazeutische Zusammensetzung enthaltend Xanthangummi
BR0207930A (pt) * 2001-03-05 2004-03-02 Ortho Mcneil Pharm Inc Composições farmacêuticas lìquidas com sabor mascarado
BR0208626A (pt) * 2001-04-03 2004-03-09 Schering Corp Composição antifúngica com biodisponibilidade intensificada
CA2455939C (fr) * 2001-07-31 2011-03-22 Wyeth Llc Preparation de sucralose permettant de masquer des gouts desagreables
US6770263B1 (en) * 2001-10-01 2004-08-03 Naturewell, Incorporated Compositions and methods for the treatment of aches and pains
US20040132823A1 (en) * 2001-11-02 2004-07-08 Leo Pavliv Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
ES2197781B1 (es) * 2001-12-04 2005-02-16 Farmalider, S.A. Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno.
US6998480B2 (en) 2002-03-08 2006-02-14 Tate & Lyle Public Limited Company Process for improving sucralose purity and yield
US7049435B2 (en) 2002-03-08 2006-05-23 Tate & Lyle Public Limited Company Extractive methods for purifying sucralose
US7300670B2 (en) 2002-04-03 2007-11-27 Unilab Pharmatech, Ltd. Oral suspension formulation
US20030232097A1 (en) * 2002-06-17 2003-12-18 Strides Inc. Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen
ATE541562T1 (de) * 2002-06-17 2012-02-15 Taro Pharmaceuticals Usa Inc Ibuprofen-suspension
KR100509432B1 (ko) * 2002-12-13 2005-08-22 주식회사 동구제약 Ｓ(+)-이부프로펜을 함유한 시럽제 조성물 및 그의 제조방법
US20040253311A1 (en) * 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
CL2003002653A1 (es) * 2002-12-18 2005-04-22 Wyeth Corp Composicion farmaceutica que comprende (a) un antiinflamatorio no esteroidal (nsaid), preferentemente ibuprofeno, (b) un descongestionante, preferentemente pseudoefedrina y (c) un antihistaminico, preferentemente clorfeniramina; metodo para su prepar
US20040186180A1 (en) * 2003-03-21 2004-09-23 Gelotte Cathy K. Non-steroidal anti-inflammatory drug dosing regimen
WO2005025622A1 (fr) * 2003-09-12 2005-03-24 Ryukakusan Co. Ltd. Boisson a base de gelee particulaire, masquant l'amertume
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
US20050095299A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
US20050095300A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
US20060088587A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070281022A1 (en) * 2004-10-27 2007-12-06 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070190133A1 (en) * 2004-10-27 2007-08-16 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088593A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088586A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US8383159B2 (en) * 2004-10-27 2013-02-26 Mcneil-Ppc, Inc. Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060087051A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060093630A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20060093631A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20060093629A1 (en) 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
US20060094760A1 (en) * 2004-11-04 2006-05-04 Fawzy Abdel A Composition, system and method of treatment of gastrointestinal disorders with nizatidine oral solution
US7611695B2 (en) * 2004-11-15 2009-11-03 Ultradent Products, Inc. Flavored hemostatic and acid etching compositions
PT2522365T (pt) 2004-11-24 2017-02-08 Meda Pharmaceuticals Inc Composições que compreendem azelastina e seus métodos de utilização
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
PT1824493E (pt) * 2004-12-06 2008-11-18 Janssen Pharmaceutica Nv Suspensão oral que compreende meloxicam
CN101400343B (zh) 2006-03-16 2012-01-11 特瑞斯制药股份有限公司 含有药物-离子交换树脂复合物的经修饰释放的制剂
GB2438287A (en) * 2006-05-19 2007-11-21 Norbrook Lab Ltd Stable aqueous suspension
US20080014275A1 (en) * 2006-07-13 2008-01-17 Buehler Gail K Pharmaceutical suspensions and related methods
CN101534795B (zh) 2006-11-21 2013-04-03 麦克内尔-Ppc股份有限公司 改进释放的镇痛悬浮液
MX2009006114A (es) * 2007-03-02 2009-11-10 Meda Pharmaceuticals Inc Composiciones que comprenden carisoprodol y metodos de uso de las mismas.
MX2009009337A (es) * 2007-03-09 2009-09-21 Hercules Inc Tiosulfato de sodio estable con base en suspensiones de polimero fluidizado de hidroxietilcelulosa para servicios de yacimientos.
US20080260837A1 (en) * 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
US20080268025A1 (en) * 2007-04-25 2008-10-30 Donald Spector Compositions Useful for Preventing Pain and Soreness Resulting from Exercise and Methods of Use
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
WO2009085959A1 (fr) 2007-12-20 2009-07-09 Organic Recovery, Llc Procédés et compositions pour la digestion de déchets organiques
CN102006867A (zh) * 2008-01-03 2011-04-06 沃根哈德研究中心 含有扑热息痛和布洛芬的口服药物混悬剂
US8436156B2 (en) * 2008-01-04 2013-05-07 Tate & Lyle Technology Limited Method for the production of sucralose
KR20100130219A (ko) * 2008-03-20 2010-12-10 테이트 앤드 라일 테크놀러지 리미티드 ３급 아미드 용매로부터 산을 제거하는 방법
US8436157B2 (en) * 2008-03-26 2013-05-07 Tate & Lyle Technology Limited Method for the production of sucralose
AR071134A1 (es) * 2008-04-03 2010-05-26 Tate & Lyle Technology Ltd Cristalizacion de sucralosa a partir de chorros que contienen sucralosa
US20090299055A1 (en) * 2008-04-03 2009-12-03 Tate & Lyle Technology Limited Purification of Sucralose Containing Feed Streams for Sucralose Crystallization
US20090259036A1 (en) * 2008-04-03 2009-10-15 Tate & Lyle Technology Limited Extraction of less polar impurities from sucralose containing aqueous feed streams
WO2009137193A2 (fr) * 2008-04-03 2009-11-12 Tate & Lyte Technology Ltd Effet de la concentration d'hydrate de carbone sur l'efficacité de l'extraction de sucralose
US8497367B2 (en) * 2008-04-03 2013-07-30 Tate & Lyle Technology Limited Sucralose purification process
SG10201914059WA (en) 2008-10-22 2020-03-30 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
WO2010103384A1 (fr) * 2009-03-13 2010-09-16 Nucitec S.A. De C.V. Compositions et méthodes de traitement et prévention de maladies cardiovasculaires
GB2469158B (en) 2009-03-31 2011-09-28 Peter J Seaberg Base-assisted formation of tin-sucrose adducts
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
GB2474311B (en) * 2009-10-12 2012-10-17 Tate & Lyle Technology Ltd Low temperature, single solvent process for the production of sucrose-6-ester
GB2474310B (en) 2009-10-12 2012-02-29 Tate & Lyle Technology Ltd Process for the production of sucrose-6-ester
GB201110520D0 (en) 2011-05-10 2011-08-03 Tate & Lyle Technology Ltd Extraction of carboxylic acids with tin compounds
EP3139769B1 (fr) 2014-05-05 2022-06-22 California Safe Soil, LLC Compositions riches en substances nutritives
CN113354649A (zh) 2014-11-16 2021-09-07 阵列生物制药公司 一种新的晶型
EP3061501A1 (fr) 2015-02-27 2016-08-31 Rottapharm Ltd. Composition pour le traitement de l'acné
EP3117825A1 (fr) 2015-07-16 2017-01-18 Rottapharm S.p.A. Formulation orale comprenant de la berbérine et un extrait de morus alba
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
CA3003153A1 (fr) 2015-10-26 2017-05-04 Loxo Oncology, Inc. Mutations ponctuelles dans le cancer resistant aux inhibiteurs de trk et methodes associees
PE20181888A1 (es) 2016-04-04 2018-12-11 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RU2745953C2 (ru) 2016-05-18 2021-04-05 Локсо Онколоджи, Инк. Способ получения (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)-пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида и его солей
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
EP3677283A4 (fr) * 2017-08-31 2021-05-12 Tohoku University Plage de pression osmotique appropriée d'une solution contenant un médicament efficace dans un système d'administration de médicament pour le système lymphatique
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US20190247398A1 (en) * 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
GB2585825B (en) * 2019-07-09 2023-03-22 Lexon Uk Holdings Ltd Suspending vehicle formulation
CN112516083B (zh) * 2020-12-15 2023-02-28 太阳升(亳州)生物医药科技有限公司 布洛芬混悬液及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB971700A (en) * 1961-02-02 1964-09-30 Boots Pure Drug Co Ltd Anti-Inflammatory Agents
US3911128A (en) * 1972-02-07 1975-10-07 Sandoz Ag Substituted purines as hypolipidemics
US3852257A (en) * 1973-02-05 1974-12-03 Kelco Co Suspension polymerization in the presence of xanthan gum
US4447454A (en) * 1977-04-01 1984-05-08 The Upjohn Company Analgetic compounds, compositions and process of treatment
US4145440A (en) * 1977-08-18 1979-03-20 The Upjohn Company Liquid suspension of an aluminum salt of ibuprofen
CA1167403A (fr) * 1979-07-10 1984-05-15 Unilever Limited Heteropolysaccharides microbiens
US4329448A (en) * 1979-07-10 1982-05-11 Lever Brothers Company Microbial heteropolysaccharide
JPS5835965B2 (ja) * 1979-07-31 1983-08-05 ライオン株式会社 口腔用組成物
JPS5846483B2 (ja) * 1979-09-20 1983-10-17 ライオン株式会社 口腔用組成物
US4251560A (en) * 1979-08-21 1981-02-17 General Foods Corporation Cream-containing frozen whipped topping composition
US4361580A (en) * 1980-06-20 1982-11-30 The Upjohn Manufacturing Company Aluminum ibuprofen pharmaceutical suspensions
US4346108A (en) * 1981-06-22 1982-08-24 The Upjohn Manufacturing Company M Method for preventing adhesion formation
US4542158A (en) * 1981-12-21 1985-09-17 Merck & Co., Inc. Prodrug esters of diflunisal and related compounds
US4762709A (en) * 1983-09-16 1988-08-09 Pennwalt Corporation Liquid prolonged release pharmaceutical formulations containing ionic constituents
IT1183574B (it) * 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
US4744986A (en) * 1986-03-07 1988-05-17 Rorer Pharmaceutical Corporation Process for the preparation of a viscosity-stable antacid composition
US4761274A (en) * 1986-03-27 1988-08-02 Warner-Lambert Company Medicament adsorbates of analgesics with complex magnesium aluminum silicate and their preparation
GB8609566D0 (en) * 1986-04-18 1986-05-21 Boots Co Plc Analgesic method
US4684666A (en) * 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
GB8702411D0 (en) * 1987-02-03 1987-03-11 Zyma Sa Swellable pellets
US4788220A (en) * 1987-07-08 1988-11-29 American Home Products Corporation (Del.) Pediatric ibuprofen compositions
US4861797A (en) * 1987-10-15 1989-08-29 Oratech Pharmaceutical Development Corporation Liquid ibuprofen compositions and methods of making them
US4975465A (en) * 1989-03-28 1990-12-04 American Home Products Corporation Orally administrable ibuprofen compositions

Also Published As

Publication number Publication date
IL94887A (en) 1994-11-11
IE902332A1 (en) 1991-01-16
ES2064634T3 (es) 1995-02-01
PT94504A (pt) 1991-02-08
PT94504B (pt) 1997-02-28
NZ234143A (en) 1991-10-25
AU5792690A (en) 1991-02-07
ATE110259T1 (de) 1994-09-15
US5374659A (en) 1994-12-20
US5621005A (en) 1997-04-15
JP2874967B2 (ja) 1999-03-24
KR910000124A (ko) 1991-01-29
DE69011766T2 (de) 1994-12-22
GR1002094B (en) 1995-12-28
GR900100481A (el) 1991-11-15
EP0405930B1 (fr) 1994-08-24
JPH0363219A (ja) 1991-03-19
GT199000066A (es) 1992-04-09
IE64400B1 (en) 1995-08-09
ZA905058B (en) 1992-02-26
IL94887A0 (en) 1991-04-15
IE902332L (en) 1990-12-28
KR0161969B1 (ko) 1998-12-01
AU635283B2 (en) 1993-03-18
HK127494A (en) 1994-11-25
CA2019863A1 (fr) 1990-12-28
EP0405930A3 (en) 1991-09-04
DE69011766D1 (de) 1994-09-29
EP0405930A2 (fr) 1991-01-02

Similar Documents

Publication Publication Date Title
CA2019863C (fr) Suspension aqueuse pharmaceutique pour des ingredients actifs pharmaceutiques peu hydrosolubles
US6806256B2 (en) Taste masked liquid pharmaceutical compositions
CA2567075C (fr) Suspension pharmaceutique
KR960011772B1 (ko) 개선된 디데옥시 퓨린 뉴클레오사이드 경구 투여 제제
EP0679400A1 (fr) Formes de doses orales de l'azithromycin pour éviter l'interaction entre d'agent et des produits alimentaires
US5730997A (en) Tastemasked liquid pharmaceutical delivery system
JP2818220B2 (ja) 食品用の含水有機溶剤抽出物含有組成物および医薬用の含水有機溶剤抽出物含有組成物、並びにそれらの製造方法
KR20070085529A (ko) 염료 비함유 약제학적 현탁액 및 관련된 방법
EP0717992A2 (fr) Formulations de suspension aqueuses pour applications pharmaceutiques
US20020006433A1 (en) Pharmaceutical formulations
US6793935B2 (en) Mineral supplement
US11617795B2 (en) Pharmaceutical syrup formulation or suspension
WO2011107617A1 (fr) Composition pharmaceutique liquide d'ibuprofène et de codéine à administrer par voie orale, son procédé de préparation et son utilisation
CA2295037A1 (fr) Compositions aqueuses contenant de la ranitidine et du saccharose lcmt

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry